Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer

Oliver Ebert, Katsunori Shinozaki, Chryssanthi Kournioti, Man-Seong Park, Adolfo García-Sastre, Savio L.C. Woo

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Vesicular stomatitis virus (VSV) selectively replicates in tumor but not in normal cells and is being developed as an oncolytic agent for cancer therapy. Here we report the construction of a recombinant VSV capable of inducing syncytia formation between tumor cells through membrane fusion at neutral pH, which led to enhanced oncolytic properties against multifocal hepatocellular carcinoma (HCC) in the livers of immunocompetent rats. Recombinant VSV vectors were constructed by insertion into their genome a transcription unit expressing a control or fusion protein derived from Newcastle disease virus. In vitro characterization of the recombinant fusogenic VSV vector on human and rat HCC cells showed extensive syncytia formation and significantly enhanced cytotoxic effects. In vivo, administration of fusogenic VSV into the hepatic artery of Buffalo rats bearing syngeneic multifocal HCC lesions in their livers resulted in syncytia formation exclusively within the tumors, and there was no collateral damage to the neighboring hepatic parenchyma. The fusogenic VSV also conferred a significant survival advantage over a nonfusogenic control virus in the treated animal (P = 0.0078, log-rank test). The results suggest that fusogenic VSV can be developed into an effective and safe therapeutic agent for cancer treatment in patients, including those with multifocal HCC in the liver.

Original languageEnglish
Pages (from-to)3265-3270
Number of pages6
JournalCancer Research
Volume64
Issue number9
DOIs
Publication statusPublished - 2004 May 1
Externally publishedYes

Fingerprint

Vesicular Stomatitis
Giant Cells
Viruses
Hepatocellular Carcinoma
Neoplasms
Liver
Newcastle disease virus
Membrane Fusion
Hepatic Artery
Buffaloes
Therapeutics
Cell Membrane
Genome
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer. / Ebert, Oliver; Shinozaki, Katsunori; Kournioti, Chryssanthi; Park, Man-Seong; García-Sastre, Adolfo; Woo, Savio L.C.

In: Cancer Research, Vol. 64, No. 9, 01.05.2004, p. 3265-3270.

Research output: Contribution to journalArticle

Ebert, Oliver ; Shinozaki, Katsunori ; Kournioti, Chryssanthi ; Park, Man-Seong ; García-Sastre, Adolfo ; Woo, Savio L.C. / Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer. In: Cancer Research. 2004 ; Vol. 64, No. 9. pp. 3265-3270.
@article{4c30abd50b90416889f605ad9e95c2b7,
title = "Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer",
abstract = "Vesicular stomatitis virus (VSV) selectively replicates in tumor but not in normal cells and is being developed as an oncolytic agent for cancer therapy. Here we report the construction of a recombinant VSV capable of inducing syncytia formation between tumor cells through membrane fusion at neutral pH, which led to enhanced oncolytic properties against multifocal hepatocellular carcinoma (HCC) in the livers of immunocompetent rats. Recombinant VSV vectors were constructed by insertion into their genome a transcription unit expressing a control or fusion protein derived from Newcastle disease virus. In vitro characterization of the recombinant fusogenic VSV vector on human and rat HCC cells showed extensive syncytia formation and significantly enhanced cytotoxic effects. In vivo, administration of fusogenic VSV into the hepatic artery of Buffalo rats bearing syngeneic multifocal HCC lesions in their livers resulted in syncytia formation exclusively within the tumors, and there was no collateral damage to the neighboring hepatic parenchyma. The fusogenic VSV also conferred a significant survival advantage over a nonfusogenic control virus in the treated animal (P = 0.0078, log-rank test). The results suggest that fusogenic VSV can be developed into an effective and safe therapeutic agent for cancer treatment in patients, including those with multifocal HCC in the liver.",
author = "Oliver Ebert and Katsunori Shinozaki and Chryssanthi Kournioti and Man-Seong Park and Adolfo Garc{\'i}a-Sastre and Woo, {Savio L.C.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-03-3753",
language = "English",
volume = "64",
pages = "3265--3270",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer

AU - Ebert, Oliver

AU - Shinozaki, Katsunori

AU - Kournioti, Chryssanthi

AU - Park, Man-Seong

AU - García-Sastre, Adolfo

AU - Woo, Savio L.C.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Vesicular stomatitis virus (VSV) selectively replicates in tumor but not in normal cells and is being developed as an oncolytic agent for cancer therapy. Here we report the construction of a recombinant VSV capable of inducing syncytia formation between tumor cells through membrane fusion at neutral pH, which led to enhanced oncolytic properties against multifocal hepatocellular carcinoma (HCC) in the livers of immunocompetent rats. Recombinant VSV vectors were constructed by insertion into their genome a transcription unit expressing a control or fusion protein derived from Newcastle disease virus. In vitro characterization of the recombinant fusogenic VSV vector on human and rat HCC cells showed extensive syncytia formation and significantly enhanced cytotoxic effects. In vivo, administration of fusogenic VSV into the hepatic artery of Buffalo rats bearing syngeneic multifocal HCC lesions in their livers resulted in syncytia formation exclusively within the tumors, and there was no collateral damage to the neighboring hepatic parenchyma. The fusogenic VSV also conferred a significant survival advantage over a nonfusogenic control virus in the treated animal (P = 0.0078, log-rank test). The results suggest that fusogenic VSV can be developed into an effective and safe therapeutic agent for cancer treatment in patients, including those with multifocal HCC in the liver.

AB - Vesicular stomatitis virus (VSV) selectively replicates in tumor but not in normal cells and is being developed as an oncolytic agent for cancer therapy. Here we report the construction of a recombinant VSV capable of inducing syncytia formation between tumor cells through membrane fusion at neutral pH, which led to enhanced oncolytic properties against multifocal hepatocellular carcinoma (HCC) in the livers of immunocompetent rats. Recombinant VSV vectors were constructed by insertion into their genome a transcription unit expressing a control or fusion protein derived from Newcastle disease virus. In vitro characterization of the recombinant fusogenic VSV vector on human and rat HCC cells showed extensive syncytia formation and significantly enhanced cytotoxic effects. In vivo, administration of fusogenic VSV into the hepatic artery of Buffalo rats bearing syngeneic multifocal HCC lesions in their livers resulted in syncytia formation exclusively within the tumors, and there was no collateral damage to the neighboring hepatic parenchyma. The fusogenic VSV also conferred a significant survival advantage over a nonfusogenic control virus in the treated animal (P = 0.0078, log-rank test). The results suggest that fusogenic VSV can be developed into an effective and safe therapeutic agent for cancer treatment in patients, including those with multifocal HCC in the liver.

UR - http://www.scopus.com/inward/record.url?scp=2342637176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342637176&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3753

DO - 10.1158/0008-5472.CAN-03-3753

M3 - Article

VL - 64

SP - 3265

EP - 3270

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -